Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Segments - Segment Information (Details)

v3.20.2
Note 14 - Segments - Segment Information (Details) - USD ($)
 3 Months Ended 6 Months Ended
Jun. 30, 2020
Mar. 31, 2020
Jun. 30, 2019
Mar. 31, 2019
Jun. 30, 2020
Jun. 30, 2019
Dec. 31, 2019
Revenue from contract with customer $ 9,000   $ 16,000   $ 24,000 $ 30,000  
Grant and other revenue 262,181   244,199   403,232 282,673  
Revenues, Total 271,101   260,092   427,373 301,716  
Cost of revenue 357   238   966 6,364  
Research and development expenses 1,281,779   1,070,642   2,281,048 1,811,225  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,310,335   1,824,874   3,121,246 3,516,611  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 19,256   36,726   36,099 73,505  
Loss from operations (3) [3] (2,340,626)   (2,672,388)   (5,011,986) (5,105,989)  
Other income (4) [4] 15,007   (1,590)   12,759 7,122  
Net loss (2,325,619) $ (2,673,608) (2,673,178) $ (2,429,061) (4,999,227) (5,102,240)  
Total assets, net of depreciation and amortization 7,106,683       7,106,683   $ 4,150,906
Capital expenditures 1,947       8,406    
Revenue from contract with customer 9,000   16,000   24,000 30,000  
Loss from operations (3) [3] (2,340,626)   (2,672,388)   (5,011,986) (5,105,989)  
Other expense (4) [4] 15,007   (1,590)   12,759 7,122  
Income tax benefit   168   (708)  
Net loss from continuing operations     (2,673,810)     (5,099,575)  
Income from discontinued operations, net of tax     632     (2,665)  
Total assets, net of depreciation and amortization: 7,106,683       7,106,683   $ 4,150,906
UNITED STATES              
Total assets, net of depreciation and amortization 6,606,683   8,123,881   6,606,683 8,123,881  
Total assets, net of depreciation and amortization: 6,606,683   8,123,881   6,606,683 8,123,881  
Non-US [Member]              
Total assets, net of depreciation and amortization     6,514     6,514  
Total assets, net of depreciation and amortization:     6,514     6,514  
Royalty [Member]              
Revenue from contract with customer 8,920   5,940   24,141 9,090  
Revenue from contract with customer 8,920   5,940   24,141 9,090  
License [Member]              
Revenue from contract with customer   9,953   9,953  
Revenue from contract with customer   9,953   9,953  
Diagnostics Segment [Member]              
Grant and other revenue 215,458   196,630   274,374 232,621  
Revenues, Total 224,378   212,523   298,515 251,664  
Cost of revenue 357   238   966 6,364  
Research and development expenses 1,193,151   775,462   2,150,777 1,516,045  
Selling, general and administrative expenses, excluding depreciation and amortization [1]      
Depreciation, Depletion and Amortization, Nonproduction, Total [2]      
Loss from operations (3) [3] (969,130)   (563,177)   (1,853,228) (1,270,745)  
Other income (4) [4]      
Net loss (969,130)   (562,510)   (1,853,228) (1,273,587)  
Capital expenditures          
Loss from operations (3) [3] (969,130)   (563,177)   (1,853,228) (1,270,745)  
Other expense (4) [4]      
Income tax benefit     35     (177)  
Net loss from continuing operations     (563,142)     (1,270,922)  
Income from discontinued operations, net of tax     632     (2,665)  
Diagnostics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 107,185   220,334   107,185 220,334  
Total assets, net of depreciation and amortization: 107,185   220,334   107,185 220,334  
Diagnostics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization     6,514     6,514  
Total assets, net of depreciation and amortization:     6,514     6,514  
Diagnostics Segment [Member] | Royalty [Member]              
Revenue from contract with customer 8,920   5,940   24,141 9,090  
Revenue from contract with customer 8,920   5,940   24,141 9,090  
Diagnostics Segment [Member] | License [Member]              
Revenue from contract with customer     9,953     9,953  
Revenue from contract with customer     9,953     9,953  
Therapeutics Segment [Member]              
Grant and other revenue 46,723   47,569   128,858 50,052  
Revenues, Total 46,723   47,569   128,858 50,052  
Cost of revenue      
Research and development expenses 88,628   295,180   130,271 295,180  
Selling, general and administrative expenses, excluding depreciation and amortization [1] 972   3,062   (550) 14,776  
Depreciation, Depletion and Amortization, Nonproduction, Total [2]      
Loss from operations (3) [3] (42,877)   (250,673)   (863) (259,904)  
Other income (4) [4]      
Net loss (42,877)   (250,657)   (863) (259,940)  
Capital expenditures          
Loss from operations (3) [3] (42,877)   (250,673)   (863) (259,904)  
Other expense (4) [4]      
Income tax benefit     16     (36)  
Net loss from continuing operations     (250,657)     (259,940)  
Income from discontinued operations, net of tax          
Therapeutics Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 36,483   11,235   36,483 11,235  
Total assets, net of depreciation and amortization: 36,483   11,235   36,483 11,235  
Therapeutics Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization          
Total assets, net of depreciation and amortization:          
Therapeutics Segment [Member] | Royalty [Member]              
Revenue from contract with customer      
Revenue from contract with customer      
Therapeutics Segment [Member] | License [Member]              
Revenue from contract with customer          
Revenue from contract with customer          
Corporate Segment [Member]              
Grant and other revenue      
Revenues, Total      
Cost of revenue      
Research and development expenses      
Selling, general and administrative expenses, excluding depreciation and amortization [1] 1,309,363   1,821,812   3,121,796 3,501,835  
Depreciation, Depletion and Amortization, Nonproduction, Total [2] 19,256   36,726   36,099 73,505  
Loss from operations (3) [3] (1,328,619)   (1,858,538)   (3,157,895) (3,575,340)  
Other income (4) [4] 15,007   (1,590)   12,759 7,122  
Net loss (1,313,612)   (1,860,011)   (3,145,136) (3,568,713)  
Capital expenditures 1,947       8,406    
Loss from operations (3) [3] (1,328,619)   (1,858,538)   (3,157,895) (3,575,340)  
Other expense (4) [4] 15,007   (1,590)   12,759 7,122  
Income tax benefit     117     (495)  
Net loss from continuing operations     (1,860,011)     (3,568,713)  
Income from discontinued operations, net of tax          
Corporate Segment [Member] | UNITED STATES              
Total assets, net of depreciation and amortization 6,463,015   7,892,312   6,463,015 7,892,312  
Total assets, net of depreciation and amortization: 6,463,015   7,892,312   6,463,015 7,892,312  
Corporate Segment [Member] | Non-US [Member]              
Total assets, net of depreciation and amortization          
Total assets, net of depreciation and amortization:          
Corporate Segment [Member] | Royalty [Member]              
Revenue from contract with customer      
Revenue from contract with customer      
Corporate Segment [Member] | License [Member]              
Revenue from contract with customer          
Revenue from contract with customer          
[1] General and administrative expenses, excluding depreciation and amortization, represent costs that relate to the general administration of the Company and as such are not currently allocated to our individual reportable segments, other than those expenses directly incurred by MT.
[2] Depreciation and amortization is reflected in selling, general and administrative expenses ($19,256 and $36,726 for the three-month periods ended June 30, 2020 and 2019, and $36,099 and $73,505 for the six-month periods ended June 30, 2020 and 2019, respectively).
[3] Loss from operations does not reflect the allocation of certain selling, general and administrative expenses, excluding depreciation and amortization, to our individual reportable segments, other than those expenses directly incurred by MT.
[4] Amounts consist primarily of interest income and interest expense, which are not currently allocated to our individual reportable segments.